摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

glycolic acid-2-hydroxybutyric acid

中文名称
——
中文别名
——
英文名称
glycolic acid-2-hydroxybutyric acid
英文别名
2-(2-Hydroxybutanoyloxy)acetic acid
glycolic acid-2-hydroxybutyric acid化学式
CAS
——
化学式
C6H10O5
mdl
——
分子量
162.142
InChiKey
OMRIADVDBQRIKD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    11
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    83.8
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    参考文献:
    名称:
    Matrix for sustained-release preparation
    摘要:
    本发明涉及一种矩阵,用于缓释制剂,其包括在直链聚酯的羧基末端形成的酯,该聚酯基本上由α-羟基单羧酸组成。该矩阵对光、热、湿度、着色等稳定,并且毒性低。使用本发明的酯制备的缓释制剂可在较长时间内提供稳定的药物释放,确保持续稳定的效果。此外,缓释制剂在给药后不会出现过量药物释放。
    公开号:
    US05594091A1
点击查看最新优质反应信息

文献信息

  • Prolonged release preparation and polymers thereof
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US05304377A1
    公开(公告)日:1994-04-19
    A polymer for a prolonged release preparation which comprises (A) a polylactic acid and (B) a copolymer of glycolic acid and a hydroxycarboxylic acid of general formula ##STR1## wherein R stands for an alkyl group having 2 to 8 carbons, wherein the weight ratio of (A) and (B) is in the range of 10/90 to 90/10. The drug is released at a constant rate from the preparation over the total release period without a large burst at the initial state. Furthermore, the drug release period of the preparation can be freely controlled by varying the blending ratio of (A) and (B).
    一种延长释放制剂的聚合物,包括(A) 聚乳酸和 (B) 一种由乙二醇酸和一般式为##STR1##的羟基羧酸的共聚物,其中 R 代表具有 2 到 8 个碳原子的烷基基团,其中 (A) 和 (B) 的重量比在 10/90 到 90/10 的范围内。药物在整个释放期间以恒定速率从制剂中释放,而不会在初始阶段出现大量释放。此外,通过改变 (A) 和 (B) 的混合比例,可以自由控制制剂的药物释放期。
  • Sustained-release preparation
    申请人:Takeda Chemical Industries, ltd.
    公开号:US05480868A1
    公开(公告)日:1996-01-02
    A sustained-release preparation which comprises a physiologically active peptide of general formula ##STR1## wherein X represents an acyl group; R.sub.1, R.sub.2 and R.sub.4 each represents an aromatic cyclic group; R.sub.3 represents a D-amino acid residue or a group of the formula ##STR2## wherein R.sub.3 ' is a heterocyclic group; R.sub.5 represents a group of the formula --(CH.sub.2).sub.n --R.sub.5 ' wherein n is 2 or 3, and R.sub.5 ' is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group; R.sub.6 represents a group of the formula --(CH.sub.2).sub.n --R.sub.6 ' wherein n is 2 or 3, and R.sub.6 ' is an amino group which may optionally be substituted; R.sub.7 represents a D-amino acid residue or an azaglycyl residue; and Q represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group. The sustained-release preparation shows a constant release of the peptide over a long time and is substantially free from an initial burst.
    一种缓释制剂,包括一种具有通式##STR1##的生理活性肽,其中X表示酰基;R.sub.1,R.sub.2和R.sub.4各自表示芳香环基;R.sub.3表示D-氨基酸残基或公式##STR2##的基团,其中R.sub.3'是杂环基团;R.sub.5表示公式--(CH.sub.2).sub.n--R.sub.5'的基团,其中n为2或3,R.sub.5'是基基团,可以选择性地被取代,芳香环基或O-糖基;R.sub.6表示公式--(CH.sub.2).sub.n--R.sub.6'的基团,其中n为2或3,R.sub.6'是基基团,可以选择性地被取代;R.sub.7表示D-氨基酸残基或氮杂甘酰残基;Q表示氢或低碳基,或其盐和具有末端羧基的可生物降解聚合物。该缓释制剂显示出肽长时间的恒定释放,且基本上没有初始突发释放。
  • [EN] OSTEOGENETIC PROMOTING PHARMACEUTICAL COMPOSITION<br/>[FR] COMPOSITION PHARMACEUTIQUE FAVORISANT L'OSTEOGENESE
    申请人:TAKEDA CHEMICAL INDUSTRIES, LTD.
    公开号:WO1996039134A1
    公开(公告)日:1996-12-12
    (EN) This invention provides a pharmaceutical composition comprising a non-peptide osteogenetic promoting substance and a biodegradable polymer, which can be safely used as a prophylactic/therapeutic agent for various bone diseases (e.g., bone fractures).(FR) La composition pharmaceutique décrite contient une substance non peptidique favorisant de l'ostéogénèse et un polymère biodégradable. Cette composition peut être utilisée sans danger comme agent prophylactique/thérapeutique de diverses maladies des os (par exemple fractures).
    这项发明提供了一种药物组合物,包括非肽骨生成促进物质和可生物降解聚合物,可安全用作各种骨疾病(如骨折)的预防/治疗剂。
  • BONE REPAIR MATERIALS/ARTIFICIAL BONE COMPOSITIONS
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1120122A1
    公开(公告)日:2001-08-01
    Bone repair materials/artificial bone compositions prepared by adding a benzothiopyran derivative or a benzothiepin derivative to a bone repair material or an artificial bone or coating a bone repair material or an artificial bone with a benzothiopyran derivative or a benzothiepin derivative for inducing the reparation of a defective site of a natural bone and strengthening the binding of the artificial bone to the natural bone in bone graft for treating fracture, etc.
    在骨修复材料或人工骨中加入苯并噻喃生物苯并噻吩生物,或在骨修复材料或人工骨上涂覆苯并噻喃生物苯并噻吩生物,制备骨修复材料/人工骨组合物,用于诱导天然骨缺损部位的修复,以及在治疗骨折的骨移植中加强人工骨与天然骨的结合等。
  • METHOD FOR PREPARING MICROSPHERE
    申请人:TANABE SEIYAKU CO., LTD.
    公开号:EP1277787A1
    公开(公告)日:2003-01-22
    It is to provide an improved method for preparation of microsphere from an emulsion wherein an organic phase containing an organic solvent having a boiling point lower than that of water and a hardly-water-soluble polymer is emulsified in an aqueous phase by an in-water drying method, which comprises: (1) using an apparatus equipped with a gas separation membrane; (2) supplying the emulsion to be subjected to in-water drying to one side of said gas separation membrane; (3) evaporating off the organic solvent contained in said emulsion to the other side of said gas separation membrane, which can remove the organic solvent with high efficiency and can be carried out in a closed system and hence is favorable from the environmental viewpoint.
    本发明旨在提供一种改进的乳液制备微球的方法,通过内干燥法将含有沸点低于的有机溶剂和难溶于的聚合物的有机相乳化在相中,该方法包括:(1) 使用装有气体分离膜的设备;(2) 向所述气体分离膜的一侧提供要进行内干燥的乳液;(3) 向所述气体分离膜的另一侧蒸发掉所述乳液中所含的有机溶剂,该方法可高效去除有机溶剂,并可在封闭系统中进行,因此从环保角度来看是有利的。
查看更多